Skip to main content

Cannabiskonsum zum Freizeitgebrauch

  • Chapter

Zusammenfassung

Zur gezielten Aufnahme, Verarbeitung und Speicherung der komplexen sensorischen Informationen unserer Umwelt benötigen wir kognitive Fähigkeiten. Unter „Kognition” versteht man dabei eine Vielzahl bewusster sowie unbewusster neuronaler Prozesse des Gehirns, die bei der Verarbeitung externer und interner Informationen ablaufen.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-662-57291-7_3
  • Chapter length: 200 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   54.99
Price excludes VAT (USA)
  • ISBN: 978-3-662-57291-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   69.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abush H, Akirav I (2012) Short- and long-term cognitive effects of chronic cannabinoids administration in late-adolescence rats. PloS one 7 (2): e31731. doi: 10.1371/journal.pone.0031731

  2. Anderson BM, Rizzo M, Block RI, Pearlson GD, O’Leary DS (2010) Sex, drugs, and cognition: effects of marijuana. J Psychoact Drugs 42 (4): 413–424. doi: 10.1080/02791072.2010.10400704

  3. Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, Torrens M, Pujol J, Farre M, Martin-Santos R (2013) Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PloS one 8 (2): e55821. doi: 10.1371/journal.pone.0055821

  4. Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005) Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 26 (2): 480–492. doi: 10.1016/j.neuroimage.2005.02.012

  5. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, Fraccaro V, Atakan Z, Martin-Santos R, O’Carroll C, Rubia K, McGuire PK (2008) Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiat 64 (11): 966–973. doi: 10.1016/j.biopsych.2008.05.011

  6. Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N (2016) Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biol Psychiat 79 (7): 557–567. doi: 10.1016/j.biopsych.2015.12.002

  7. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76 (1): 70–81. doi: 10.1016/j.neuron.2012.09.020

  8. Chan RC, Wang Y, Ma Z, Hong XH, Yuan Y, Yu X, Li Z, Shum D, Gong QY (2008) Objective measures of prospective memory do not correlate with subjective complaints in schizophrenia. Schizophr Res 103 (1–3): 229–239. doi: 10.1016/j.schres.2008.02.019

  9. Chang L, Yakupov R, Cloak C, Ernst T (2006) Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 129 (Pt 5): 1096–1112. doi: 10.1093/brain/awl064

  10. Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci 92 (8–9): 476–481. doi: 10.1016/j.lfs.2012.06.009

  11. Crane NA, Schuster RM, Gonzalez R (2013) Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. JINS 19 (9): 1009–1015. doi: 10.1017/s135561771300088X

  12. D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (8): 1558–1572. doi: 10.1038/sj.npp.1300496

  13. D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J (2008) Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33 (10): 2505–2516. doi: 10.1038/sj.npp.1301643

  14. De Bellis MD, Wang L, Bergman SR, Yaxley RH, Hooper SR, Huettel SA (2013) Neural mechanisms of risky decision-making and reward response in adolescent onset cannabis use disorder. Drug Alcohol Depend 133 (1): 134–145. doi: 10.1016/j.drugalcdep.2013.05.020

  15. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in Cannabis Potency Over the Last 2 Decades (1995–2014): Analysis of Current Data in the United States. Biol Psychiat 79 (7): 613–619. doi: 10.1016/j.biopsych.2016.01.004

  16. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxford, England) 27 (1): 19–27. doi: 10.1177/0269881112460109

  17. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011) Cannabis use before age 15 and subsequent executive functioning. Br J Psychiat 198 (6): 442–447. doi: 10.1192/bjp.bp.110.077479

  18. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83 (3): 1017–1066. doi: 10.1152/physrev.00004.2003

  19. Fridberg DJ, Queller S, Ahn W-Y, Kim W, Bishara AJ, Busemeyer JR, Porrino L, Stout JC (2010) Cognitive mechanisms underlying risky decision-making in chronic cannabis users. J Math Psychol 54 (1): 28–38. doi: https://doi.org/10.1016/j.jmp.2009.10.002

  20. Fried PA, Watkinson B, Gray R (2005) Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicol Teratol 27 (2): 231–239. doi: 10.1016/j.ntt.2004.11.003

  21. Ganzer F, Broning S, Kraft S, Sack PM, Thomasius R (2016) Weighing the Evidence: A Systematic Review on Long-Term Neurocognitive Effects of Cannabis Use in Abstinent Adolescents and Adults. Neuropsychol Rev 26 (2): 186–222. doi: 10.1007/s11065-016-9316-2

  22. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Killgore WD (2012) Age of onset of marijuana use impacts inhibitory processing. Neurosci Lett 511 (2): 89–94. doi: 10.1016/j.neulet.2012.01.039

  23. Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, Koehl M, Abrous DN, Mendizabal-Zubiaga J, Grandes P, Liu Q, Bai G, Wang W, Xiong L, Ren W, Marsicano G, Zhang X (2012) Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148 (5): 1039–1050. doi: 10.1016/j.cell.2012.01.037

  24. Hanson KL, Thayer RE, Tapert SF (2014) Adolescent marijuana users have elevated risk-taking on the balloon analog risk task. J Psychopharmacol (Oxford, England) 28 (11): 1080–1087. doi: 10.1177/0269881114550352

  25. Harvey MA, Sellman JD, Porter RJ, Frampton CM (2007) The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev 26 (3): 309–319. doi: 10.1080/09595230701247772

  26. Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, Busquets-Garcia A, Pagano Zottola AC, Delamarre A, Cannich A, Vincent P, Varilh M, Robin LM, Terral G, Garcia-Fernandez MD, Colavita M, Mazier W, Drago F, Puente N, Reguero L, Elezgarai I, Dupuy JW, Cota D, Lopez-Rodriguez ML, Barreda-Gomez G, Massa F, Grandes P, Benard G, Marsicano G (2016) A cannabinoid link between mitochondria and memory. Nature 539 (7630): 555–559. doi: 10.1038/nature20127

  27. Hermann D, Schneider M (2012) Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharmaceut Design 18 (32): 4897–4905

    Google Scholar 

  28. Hester R, Nestor L, Garavan H (2009) Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 34 (11): 2450–2458. doi: 10.1038/npp.2009.67

  29. Hu SS, Mackie K (2015) Distribution of the Endocannabinoid System in the Central Nervous System. Handb Exp Pharmacol 231: 59–93. doi: 10.1007/978-3-319-20825-1_3

  30. Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4 (8): 1770–1804. doi: 10.1002/cbdv.200790152

  31. Iversen L (2003) Cannabis and the brain. Brain 126 (6): 1252–1270. doi: 10.1093/brain/awg143

  32. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, McGue M, Raine A, Baker LA (2016) Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci USA 113 (5): E500–508. doi: 10.1073/pnas.1516648113

  33. Jacobsen LK, Pugh KR, Constable RT, Westerveld M, Mencl WE (2007) Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users. Biol Psychiat 61 (1): 31–40. doi: 10.1016/j.biopsych.2006.02.014

  34. Jacobus J, Goldenberg D, Wierenga CE, Tolentino NJ, Liu TT, Tapert SF (2012) Altered cerebral blood flow and neurocognitive correlates in adolescent cannabis users. Psychopharmacology 222 (4): 675–684. doi: 10.1007/s00213-012-2674-4

  35. James A, James C, Thwaites T (2013) The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiat Res 214 (3): 181–189. doi: 10.1016/j.pscychresns.2013.07.012

  36. Kambeitz JP, Bhattacharyya S, Kambeitz-Ilankovic LM, Valli I, Collier DA, McGuire P (2012) Effect of BDNF val (66)met polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci Biobehav Rev 36 (9): 2165–2177. doi: 10.1016/j.neubiorev.2012.07.002

  37. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89 (1): 309–380. doi: 10.1152/physrev.00019.2008

  38. Lane SD, Cherek DR, Tcheremissine OV, Steinberg JL, Sharon JL (2007) Response perseveration and adaptation in heavy marijuana-smoking adolescents. Addict Behav 32 (5): 977–990. doi: 10.1016/j.addbeh.2006.07.007

  39. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895

  40. Lisdahl KM, Price JS (2012) Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. JINS 18 (4): 678–688. doi: 10.1017/s1355617712000276

  41. Lorenzetti V, Solowij N, Yucel M (2016) The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biol Psychiat 79 (7): e17–31. doi: 10.1016/j.biopsych.2015.11.013

  42. Lutz B, Marsicano G, Maldonado R, Hillard CJ (2015) The endocannabinoid system in guarding against fear, anxiety and stress. Nature Rev Neurosci 16 (12): 705–718. doi: 10.1038/nrn4036

  43. Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT (2004) Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med 34 (7): 1239–1250

    Google Scholar 

  44. Makela P, Wakeley J, Gijsman H, Robson PJ, Bhagwagar Z, Rogers RD (2006) Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. Neuropsychopharmacology 31 (2): 462–470. doi: 10.1038/sj.npp.1300871

  45. Martin-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, Allen P, Fusar-Poli P, Borgwardt S, Seal M, Busatto GF, McGuire P (2010) Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 40 (3): 383–398. doi: 10.1017/s0033291709990729

  46. Mato S, Robbe D, Puente N, Grandes P, Manzoni OJ (2005) Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure. J Neurosci 25 (50): 11619–11627. doi: 10.1523/jneurosci.2294-05.2005

  47. McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF (2011) Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 224 (1): 128–134. doi: 10.1016/j.bbr.2011.05.031

  48. Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF (2007) Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. JINS 13 (5): 807–820. doi: 10.1017/s1355617707071032

  49. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF (2009) Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol 14 (4): 457–468. doi: 10.1111/j.1369-1600.2009.00166.x

  50. Medina KL, Nagel BJ, Tapert SF (2010) Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiat Res 182 (2): 152–159. doi: 10.1016/j.pscychresns.2009.12.004

  51. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109 (40): E2657–2664. doi: 10.1073/pnas.1206820109

  52. Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joels M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11 (2): 141–168. doi: 10.1038/nrd3628

  53. Mokrysz C, Landy R, Gage SH, Munafo MR, Roiser JP, Curran HV (2016) Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol (Oxford, England) 30 (2): 159–168. doi: 10.1177/0269881115622241

  54. Morgan CJ, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiat 197 (4): 285–290. doi: 10.1192/bjp.bp.110.077503

  55. O’Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, Ponto LB, Watkins GL, Hurtig RR, Hichwa RD (2002) Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26 (6): 802–816. doi: 10.1016/s0893-133X(01)00425-0

  56. O’Leary DS, Block RI, Koeppel JA, Schultz SK, Magnotta VA, Ponto LB, Watkins GL, Hichwa RD (2007) Effects of smoking marijuana on focal attention and brain blood flow. Human Psychopharmacol 22 (3): 135–148. doi: 10.1002/hup.832

  57. O’Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, Watkins GL, Hichwa RD, Andreasen NC (2003) Marijuana alters the human cerebellar clock. Neuroreport 14 (8): 1145–1151. doi: 10.1097/01.wnr.0000075420.59944.20

  58. OCEBM (2011) The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine, 2 edn. http://www.cebm.net/index.aspx?o = 5653,

  59. Padula CB, Schweinsburg AD, Tapert SF (2007) Spatial working memory performance and fMRI activation interaction in abstinent adolescent marijuana users. Psychol Addict Behav 21 (4): 478–487. doi: 10.1037/0893-164X.21.4.478

  60. Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, Lengrich

    Google Scholar 

  61. Pope HG, Jr., Jacobs A, Mialet JP, Yurgelun-Todd D, Gruber S (1997) Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosomat 66 (4): 179–184

    Google Scholar 

  62. Pope HG, Jr., Yurgelun-Todd D (1996) The residual cognitive effects of heavy marijuana use in college students. JAMA 275 (7): 521–527

    Google Scholar 

  63. Quickfall J, Crockford D (2006) Brain neuroimaging in cannabis use: a review. J Neuropsychiat Clin Neurosci 18 (3): 318–332. doi: 10.1176/jnp.2006.18.3.318

  64. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS (2008) Adolescent rats find repeated Delta (9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33 (5): 1113–1126. doi: 10.1038/sj.npp.1301475

  65. Raber JC, Elzinga S, Kaplan C (2015) Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci 40 (6): 797–803. doi: 10.2131/jts.40.797

  66. Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D’Souza DC (2012) Naltrexone does not attenuate the effects of intravenous Delta9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol 15 (9): 1251–1264. doi: 10.1017/s1461145711001830

  67. Renard J, Krebs MO, Jay TM, Le Pen G (2013) Longterm cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology 225 (4): 781–790. doi: 10.1007/s00213-012-2865-z

  68. Rubino T, Realini N, Braida D, Guidi S, Capurro V, Vigano D, Guidali C, Pinter M, Sala M, Bartesaghi R, Parolaro D (2009) Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19 (8): 763–772. doi: 10.1002/hipo.20554

  69. Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13 (2): 253–263. doi: 10.1111/j.1369-1600.2008.00110.x

  70. Schneider M (2013) Adolescence as a vulnerable period to alter rodent behavior. Cell tissue Res 354 (1): 99–106. doi: 10.1007/s00441-013-1581-2

  71. Schneider M, Kasanetz F, Lynch DL, Friemel CM, Lassalle O, Hurst DP, Steindel F, Monory K, Schafer C, Miederer I, Leweke FM, Schreckenberger M, Lutz B, Reggio PH, Manzoni OJ, Spanagel R (2015) Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. J Neurosci 35 (41): 13975–13988. doi: 10.1523/jneurosci.1937-15.2015

  72. Schneider M, Levant B, Reichel M, Gulbins E, Kornhuber J, Müller CP (2016) Lipids in psychiatric disorders and preventive medicine. Neurosci Biobehav Rev doi: https://doi.org/10.1016/j.neubiorev.2016.06.002

  73. Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM (2011) A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Human Psychopharmacol 26 (3): 224–236. doi: 10.1002/hup.1196

  74. Schoeler T, Kambeitz J, Behlke I, Murray R, Bhattacharyya S (2016) The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med 46 (1): 177–188. doi: 10.1017/s0033291715001646

  75. Schreiner AM, Dunn ME (2012) Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol 20 (5): 420–429. doi: 10.1037/a0029117

  76. Sharma P, Murthy P, Bharath MM (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiat 7 (4): 149–156

    Google Scholar 

  77. SIGN (2015) Scottish Intercollegiate Guidelines Network 50 Methodology Checklist. Edinburgh, United Kingdom

    Google Scholar 

  78. Solowij N, Battisti R (2008) The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1 (1): 81–98

    Google Scholar 

  79. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, Pesa N, Lubman DI, Yucel M (2012) Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology 219 (2): 575–586. doi: 10.1007/s00213-011-2486-y

  80. Specht K, Willmes K, Shah NJ, Jäncke L (2003) Assessment of reliability in functional imaging studiesJ MRI 17 (4): 463–471

    Google Scholar 

  81. Szutorisz H, Hurd YL (2016) Epigenetic Effects of Cannabis Exposure. Biol Psychiat 79 (7): 586–594. doi: 10.1016/j.biopsych.2015.09.014

  82. Thames AD, Arbid N, Sayegh P (2014) Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav 39 (5): 994–999. doi: 10.1016/j.addbeh.2014.01.019

  83. Verdejo-Garcia A, Benbrook A, Funderburk F, David P, Cadet J-L, Bolla KI (2007) The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend 90 (1): 2–11. doi: 10.1016/j.drugalcdep.2007.02.004

  84. Wechsler D (1944) The measurement of adult intelligence. Department of Psychology Princeton University Princeton, New Jersey. Williams and Wilkins, Baltimore

    Google Scholar 

  85. Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, Chisin R, Mechoulam R, Bar-Hamburger R, Freedman N, Even-Sapir E (2008) Brain imaging study of the acute effects of Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology 196 (1): 119–131. doi: 10.1007/s00213-007-0940-7

  86. Wong A, Montebello ME, Norberg MM, Rooney K, Lintzeris N, Bruno R, Booth J, Arnold JC, McGregor IS (2013) Exercise increases plasma THC concentrations in regular cannabis users. Drug Alcohol Depend 133 (2): 763–767. doi: 10.1016/j.drugalcdep.2013.07.031

  87. Wotjak CT (2005) Role of endogenous cannabinoids in cognition and emotionality. Mini Rev Med Chem 5 (7): 659–670

    Google Scholar 

  88. Wrege J, Schmidt A, Walter A, Smieskova R, Bendfeldt K, Radue EW, Lang UE, Borgwardt S (2014) Effects of cannabis on impulsivity: a systematic review of neuroimaging findings. Curr Pharmaceut Design 20 (13): 2126–2137

    Google Scholar 

  89. Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S (2011) Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 5: 57. doi: 10.3389/fnbeh.2011.00057

  90. https://www.phenxtoolkit.org/index.php

  91. Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A, Robinson G, Beasley R (2007) Effects of cannabis on pulmonary structure, function and symptoms. Thorax 62 (12): 1058–1063

    Google Scholar 

  92. Andreasson S, Allebeck P (1990) Cannabis and mortality among young men: a longitudinal study of Swedish conscripts. Scand J Soc Med 18 (1): 9–15

    Google Scholar 

  93. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008) Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 20 (Suppl 1): 69–74

    Google Scholar 

  94. Bailey J, Cunny H, Paule M, Slikker WJ (1987) Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90 (2): 315–321

    Google Scholar 

  95. Barber P, Pridmore H, Krishnamurthy V, Roberts S, Spriggs D, Carter KN, Anderson N (2013) Cannabis, ischemic stroke, and transient ischemic attack: a case-control study. Stroke 44 (8): 2327–2329

    Google Scholar 

  96. Beaconsfield P, Ginsburg J, Rainsbury R (1972) Marijuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med 287 (5): 209–212

    Google Scholar 

  97. Beautrais A, Joyce P, RT M (1999) Cannabis abuse and serious suicide attempts. Addiction 94 (8): 1155–1164

    Google Scholar 

  98. Birnbaum B, Pinzone J (2008) Sickle cell trait and priapism: a case report and review of the literature. Cases J 30 (1): 429

    Google Scholar 

  99. Biro T, Toth B, Hasko G, Paus R, Pacher P (2009) The endocannabinoid system of the skin in health and disease: novel perspectives and theapeutic opportunities. Trends Pharmacol Sci 30 (8): 411–420

    Google Scholar 

  100. Calabria B, Degenhardt L, Hall W, Lynskey M (2010) Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 29 (3): 318–330

    Google Scholar 

  101. Callaghan R, Allebeck P, Sidorchuk A (2013) Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 24 (10): 1811–1820

    Google Scholar 

  102. Cappelli F, Lazzeri C, Gensini GF, Valente S (2008) Cannabis: a trigger for acute myocardial infarction? A case report. J Cardiovasc Med 9 (7): 725–728

    Google Scholar 

  103. Chacko J, Heiner J, Siu W, Macy M, MK T (2006) Association between marijuana use and transitional cell carcinoma. Urology 67 (1): 100–104

    Google Scholar 

  104. Charles R, Holt S, Kirkham N (1979) Myocardial infarction and marijuana. Clin Toxicol 14 (4): 433–438

    Google Scholar 

  105. Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci 92 (8–9): 476–481. doi: 10.1016/j.lfs.2012.06.009

  106. Daling J, Doody D, Sun X, Trabert BL, Weiss N, Chen S, Biggs M, Starr J, Dey S, Schwartz S (2009) Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 115 (6): 1215–1223

    Google Scholar 

  107. Day N, Goldschmidt L, CA T (2006) Prenatal marijuana exposure contributes to the prediction of marijuana use at age 14. Addiction 101 (9): 1313–1322

    Google Scholar 

  108. Day N, Leech S, Goldschmidt L (2011) The effects of prenatal marijuana exposure on delinquent behaviours are mediated by measures of neuocognitive functioning. Neurotoxicol Teratol 33 (1): 129–136

    Google Scholar 

  109. de Carvalho M, Dourado M, Fernandes I, Araujo C, Mesquita A, Ramos-Jorge M (2015) Head and neck cancer among marijuana users: a meta-analysis of matched case-control studies. Arch Oral Biol 60 (12): 1750–1755

    Google Scholar 

  110. Duchene C, Olindo S, Chausson N, Jeannin S, Cohen-Tenoudji P, Smadja D (2010) Cannabis-induced cerebral and myocardial infarction in a young woman. Rev Neurol (Paris) 166 (4): 438–442

    Google Scholar 

  111. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in Cannabis Potency Over the Last 2 Decades (1995–2014): Analysis of Current Data in the United States. Biol Psychiat 79 (7): 613–619. doi: 10.1016/j.biopsych.2016.01.004

  112. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister A (2007) Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 293 (1): G137–145

    Google Scholar 

  113. Esse K, Fossati-Bellani M, traylor A, Martin-Schild S (2011) Epidemic of illicit drug use, mechanisms of action/addiction and stroke as a health hazard. Brain Behav 1 (1): 44–54

    Google Scholar 

  114. Feng B, Khyatti M, Ben-Ayoub W, Dahmoul S, Ayad M, Maachi F, Bedadra W, Abdoun M, Mesli S, Bakkali H, Jalbout M, Hamdi-Cherif M, Boualga K, Bouaouina N, Chouchane L, Benider A, Ben-Ayed F, Goldgar D, Corbex M (2009) Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer 101 (7): 1207–1212

    Google Scholar 

  115. Fergusson D, Horwood L, Swain-Campbell N (2002) Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97 (9): 1123–1135

    Google Scholar 

  116. Forrester M, Merz R (2007) Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986–2002. J Toxicol Environ Health A 70 (1): 7–18

    Google Scholar 

  117. Fredericks A, Benowitz N, Savanapridi C (1981) The cardiovascular and autonomic effect of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. J Pharmacol Exp Ther 216 (2): 247–253

    Google Scholar 

  118. Fried P, Watkinson B (2001) Differential effects on faces of attention in adolescents prenatally exposed to cigarettes and marijuana. Neurotoxicol Teratol 23 (5): 421–430

    Google Scholar 

  119. Fried P, Watkinson B, Gray R (2003) Differential effects on cognitive functioning in 13- to 16-years-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 25 (4): 427–436

    Google Scholar 

  120. Gillison M, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100 (6): 407–420

    Google Scholar 

  121. Goyal H, Awad H, Ghali J (2017) Role of cannabis in cardiovascular disorder. J Thorac Dis 9 (7): 2079–2092

    Google Scholar 

  122. Greenland S, Richwald G, Honda G (1983) The effects of marijuana use during pregnancy. A study in a low risk home-delivery population. Drug Alcohol Depend 11 (3–4): 359–366

    Google Scholar 

  123. Greenland S, Staisch K, Brown N, Gross S (1982) Effects of marijuana on human pregnancy, labor, and delivery. Neurobeh Toxicol Teratol 4 (4): 447–450

    Google Scholar 

  124. Grotenhermen F (2010) Cannabis-associated arteritis. Vasa 39 (1): 43–53

    Google Scholar 

  125. Gunn J, Rosales C, Center K, Nunez A, Gibson S, Christ C, Ehiri J (2016) Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. Br Med J Open 6 (4): e009986

    Google Scholar 

  126. Gurney J, Shaw C, Stanley J, Signal V, Sarfati D (2015) Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer 15 (897)

    Google Scholar 

  127. Hackam D (2015) Cannabis and stroke: systematic appraisal of case reports. Stroke 46 (3): 852–856

    Google Scholar 

  128. Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor cecrosis factor alpha-converting enzyme (TACE/ADAM17) – mediated transactivation of the epidermal growth factor receptor. Cancer 64 (6): 1943–1950

    Google Scholar 

  129. Hartung B, Kauferstein S, Ritz-Timme S, Daldrup T (2014) Sudden unexpected death under acute influence of cannabis. Forensic Sci Int 237: e11–13

    Google Scholar 

  130. Hashibe M, Morgenstern H, Cui Y, Tashkin D, Zhang Z, Cozen W, Mack T, Greenland S (2006) Marijuana use and the risk of lung and upper aerodigestive tract cancers: resulsts of a population-based case-control study. Cancer Epidemiol Biomarkers 15 (10): 1829–1834

    Google Scholar 

  131. Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, UW P (2015) Risks associated with the non-medicinal use of cannabis. Dtsch Ärztebl Int 112 (16): 271–278

    Google Scholar 

  132. Hu SS, Mackie K (2015) Distribution of the Endocannabinoid System in the Central Nervous System. Handb Exp Pharmacol 231: 59–93. doi: 10.1007/978-3-319-20825-1_3

  133. Huang Y, Zhang Z, Tashkin D, Feng B, Straif K, Hashibe M (2015) An epidemiological review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers 24 (1): 15–31

    Google Scholar 

  134. Irner T (2012) Substance exposure in utero and developmental consequences in adolescence. Child Neuropsychol 18 (6): 521–549

    Google Scholar 

  135. Jones R (2002) Cardiovascular system effects of marijuana. J Clin Pharmacol 42 (11 Suppl): 58S–63S

    Google Scholar 

  136. Kanakis C, Jr,, Pouget J, Rosen K (1976) The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation 53 (4): 703–707

    Google Scholar 

  137. Korantzopoulos P, Liu T, Papaioannides D, Li G, Goudevenos J (2008) Atrial fibrillation and marijuana smoking. Int J Clin Pract 62 (2): 308–313

    Google Scholar 

  138. Kotsalou I, Beorgoulias P, Karydas I, Fourlis S, Sioka C, Zouboulidis A, Demakopoulos N (2007) A rare case of myocardial infarction and ischemia in a cannabis-addicted patient. Clin Nucl Med 32 (2): 130–131

    Google Scholar 

  139. Kreuter M, Nowak D, Ruther T, Hoch E, Thomasius R, Vogelberg C, Brockstedt M, Hellmann A, Gohlke H, Jany B, Loddenkemper R (2016) Cannabis-Position Paper of the German Respiratory Society (DGP). Pneumologie 70 (2): 87–97

    Google Scholar 

  140. Kung H, Pearson J, Liu X (2003) Risk factors for male and female suicide decedents ages 15–64 in the United States. Results from the 1993 National Mortality Followback Survey. Soc Psychiatry Psychiatr Epidemiol 38 (8): 419–426

    Google Scholar 

  141. Lacson J, Carroll J, Tuazon E, Castelao E, Bernstein L, Cortessis V (2012) Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer 118 (21): 5374–5383

    Google Scholar 

  142. Lambrecht G, Malbrain M, Coremans P, Verbist L, Verhaegen H (1995) Acute renal infarction and heavy marijuana smoking. Nephron 70 (4): 494–496

    Google Scholar 

  143. Landfield P, Cadwallader L, Vinsant S (1988) Quantitative changes in hippocampal structure following long-term exposure. Brain Res 443 (1–2): 47–62

    Google Scholar 

  144. Lee M, Hancox R (2011) Effects of smoking cannabis on lung functions. Expert Rev Respir Med 5 (4): 537–546

    Google Scholar 

  145. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895

  146. Liang C, McClean M, Marsit C, Christensen B, Peters E, Nelson H, Kelsey K (2009) A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prevent Res (Phila) 2 (8): 759–768

    Google Scholar 

  147. Lorenzetti V, Lubman D, Whittle S, Solowij N, Yucel M (2010) Structural MRI findings in long-term cannabis users: what do we know? Substance Use Misuse 45 (11): 1787–1808

    Google Scholar 

  148. Lorenzetti V, Solowij N, Yucel M (2016) The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biol Psychiat 79 (7): e17–31. doi: 10.1016/j.biopsych.2015.11.013

  149. Lu H-C, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiat 79 (7): 516–525

    Google Scholar 

  150. Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36 (5): 277–296. doi: 10.1016/j.tips.2015.02.008

  151. Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T (2014) Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci 15 (12): 786–801. doi: 10.1038/nrn3846

  152. Marks M, Chaturvedi A, Kelsey K, Straif K, Berthiller J, Schwartz S, Smith E, Wyss A, Brennan P, Olshan A, Wei Q, Sturgis E, Zhang Z-F, Morgenstern H, Muscat J, Lazarus P, McClean M, Chen C, Vaughan T, Wunsch-Filho V, Curado M, Koifman S, Mathos E, Menez A, Daudt A, Fernandez L, Posner M, Boffetta P, Lee Y, Hashibe M, D’Souza G (2014) Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. cancer Epidemiol Biomarkers Prevent 23 (1): 160–171

    Google Scholar 

  153. Martinez-Martinez E, Martin-Ruiz A, Martin P, Calvo V, Provencio M, Garcia J (2016) CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3beta signaling pathway. Oncotarget 7 (42): 68781–68791

    Google Scholar 

  154. McQueeny T, Padula C, Price J, Medinak K, Logan P, Tapert S (2011) Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 224 (1): 128–134

    Google Scholar 

  155. Mehra R, Moore B, Crothers K, Tetrault J, Fiellin D (2006) The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 166 (13): 1359–1367

    Google Scholar 

  156. Montisci M, Thiene G, Ferrara S, Basso C (2008) Cannabis and cocaine: a lethal cocktail triggering coronary sudden death. Cardiovasc Pathol 17 (5): 344–346

    Google Scholar 

  157. Moretti S, Franchi S, Castelli M, Amodeo G, Somaini L, Panerai A, Scacerdote P (2015) Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippycampus Similar to that Observed for Peripheral Macrophages. J Neuroimmune Pharmacol 10 (2): 371–379

    Google Scholar 

  158. Mukamal K, Maclure M, Muller J, Mittleman M (2008) An exploratory prospective study of marijuana use and mortality following acute myodardial infarction. Am Heart J 155 (3): 465–470

    Google Scholar 

  159. O’Sullivan S, Tarling E, Bennett A, Kendall D, Randall M (2005) Novel time-dependent vascular actions of Delta9-tetrahydrocannabino mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337 (3): 824–831

    Google Scholar 

  160. OCEBM (2011) Levels of Evidence Working Group. The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford

  161. Perez-Lopez F, Larrad-Mur L, Kallen A, Chedraui P, Taylor H (2010) Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 17 (6): 511–531

    Google Scholar 

  162. Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, Lengerich

    Google Scholar 

  163. Pisanti S, Picardi P, D’Alessandro A, Laezza C, Bifulco M (2013) The endocannabinoid signaling system in cancer. Trends Pharmacol Sci 34 (5): 273–282

    Google Scholar 

  164. Plange N, Arend K, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A, Huth J, Sponsel W, Remky A (2007) Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 143 (1): 173–174

    Google Scholar 

  165. Reece A (2009) Chronic toxicology of cannabis. Clin Toxicol (Philadelphia, Pa) 47 (6): 517–524

    Google Scholar 

  166. Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, Fusar-Poli P (2013) Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. Psachiat Clin Neurosci 67 (7): 483–492

    Google Scholar 

  167. Scallet A, Uemura E, Andrews A, Ali S, McMillan D, Paule M, Brown RM, Slikker W, Jr., (1987) Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 436 (1): 193–198

    Google Scholar 

  168. Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13 (2): 253–263

    Google Scholar 

  169. Schneider M, Kasanetz F, Lynch D, Friemel C, Hurst D, Steindel F, Monory K, Schafer C, Miederer I, Leweke F, Schreckenberger M, Lutz B, Reggio P, Manzoni OJ, Spanagel R (2015) Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. J Neurosci 35 (41): 13975–13988

    Google Scholar 

  170. Sidney S (2002) Cardiovascular consequences of marijuana use. J Clin Pharmacol 42 (11 Suppl): 64S–70S

    Google Scholar 

  171. Sidney S, Beck J, Tekawa I, Quesenberry C, Friedman G (1997a) Marijuana use and mortality. Am J Public Health 87 (4): 585–590

    Google Scholar 

  172. Sidney S, Quesenberry C, Friedman G, Tekawa I (1997b) Marijuana use and cancer incidence (California, United States). Cancer Causes Control 8 (5): 722–728

    Google Scholar 

  173. SIGN (2015) Scottish Intercollegiate Guidelines Network, SIGN 50 Methodology Checklist. Edinburgh, United Kingdom

    Google Scholar 

  174. Sridhar K, Raub W, Metsch L, Surrat HL, Inciardi J, Duncan R, Anwyl R, McCoy C (1994) Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age. J Psychoact Drugs 26 (3): 285–288

    Google Scholar 

  175. Stanley C, Hind W, Tufarelli C, O’Sullivan S (2016) The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries. Pharmacol Res 113 (Pt A): 356–363

    Google Scholar 

  176. Sterne J, Ducastaing C (1960) Arteritis caused by Cannabis indica. Arch Mal Coeur Vaiss Feb (53): 143–147

    Google Scholar 

  177. Storr M, Devlin S, Kaplan G, Panaccione R, Andrews C (2014) Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflammatory bowel diseases 20 (3): 472–480

    Google Scholar 

  178. Swift W, Wong A, Arnold J, MdGregor I (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PloS one 8 (7): e70052. doi: 10.1371/journal.pone.0070052. Print 2013

  179. Tan C, Hatam N, Treasure T (2006) Bullous disease of the lung and cannabis smoking: insufficient evidence for a causative link. J R Soc Med 99 (2): 77–80

    Google Scholar 

  180. Tashkin D, Shapiro B, Frank I (1976) Acute effects of marihuana on airway dynamics in spontaneous and experimentally produced bronchial asthma. In: McBraude, Szara S (eds) The pharmacology of Marihuana. Raven Press, New York

    Google Scholar 

  181. Taylor F, 3rd (1988) Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South Med J 81 (10): 1213–1216

    Google Scholar 

  182. Tetrault J, Crothers K, Moore B, Mehra R, Concato J, Fiellin D (2007) Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 167 (3): 221–228

    Google Scholar 

  183. Ting J (2007) Reversible cardiomyopathy associated with acute inhaled marijuana use in a young adult. Clin Toxicol (Philadelphia, Pa) 45 (4): 432–434

    Google Scholar 

  184. Trabert B, Sigurdson A, Sweeney A, Strom S, McGlynn K (2011) Marijuana use and testicular germ cell tumors. Cancer 117 (4): 848–853

    Google Scholar 

  185. van Gelder M, Reefhuis J, Caton A, Werler M, Druschel C, Roeleveld N (2009) Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology 20 (1): 60–66

    Google Scholar 

  186. van Skike C, Maggio S, Reynolds A, Casey E, Bardo M, Dwoskin L, Prendergast M, Nixon K (2016) Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Prog Neuropsychopharmacol Biol Psychiat 65: 269–287

    Google Scholar 

  187. Vassalle C, Simoncini T, Chedraui P, Perez-Lopez F (2012) Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol 28 (9): 746–751

    Google Scholar 

  188. Weinsheimer R, Yanchar N (2008) Impact of maternal substance abuse and smoking on children with gastroschisis. J Pediatr Surg 43 (5): 879–883

    Google Scholar 

  189. Westover A, McBride S, Haley R (2007) Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiat 64 (4): 495–502

    Google Scholar 

  190. Wilcox H, Anthony J (2004) The development of suicide ideation and attempts: an epidemiologic study of first graders followed into young adulthood. Drug Alcohol Depend Dec 7 (76 Suppl): S53–67

    Google Scholar 

  191. Williams J, Ross L (2007) Consequence of prenatal toxin exposure for mental health in children and adolescents: a systematic review. Eur Child Adolesc Psychiat 16 (4): 243–253

    Google Scholar 

  192. Zhang L, Morgenstern H, Greenland S, Chang S, Lazarus P, Teare M, Woll P, Orlow I, Cox B, Brhane Y, Liu G, Hung R (2015) Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. Int J Cancer 36 (4): 894–903

    Google Scholar 

  193. Zhang Z, Morgenstern H, Spitz M, Tashkin D, Yu G, Marshall J, Hsu T, Schantz S (1999) Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers 8 (12): 1071–1078

    Google Scholar 

  194. Aloise-Young PA, Chavez EL (2002) Not all school dropouts are the same: Ethnic differences in the relation between reason for leaving school and adolescent substance use. Psychol Schools 39 (5): 539–547

    Google Scholar 

  195. Amsterdam Jv, Nutt D, Phillips L, Brink Wvd (2015) European rating of drug harms. J Psychopharmacol 29 (6): 655–660. doi: 10.1177/0269881115581980

  196. Andréasson S, Allebeck P, Engström A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2: 1483

    Google Scholar 

  197. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J 325 (7374): 1212–1213

    Google Scholar 

  198. Arseneault L, Moffitt TE, Caspi A, Taylor PJ, Silva PA (2000) Mental disorders and violence in a total birth cohort: results from the Dunedin Study. Arch Gen Psychiat 57 (10): 979–986

    Google Scholar 

  199. Beauvais F, Chavez EL, Oetting ER, Deffenbacher JL, Cornell GR (1996) Drug use, violence, and victimization among White American, Mexican American, and American Indian dropouts, students with academic problems, and students in good academic standing. J Counsel Psychol 43 (3): 292

    Google Scholar 

  200. Bray JW, Zarkin GA, Ringwalt C, Qi J (2000) The relationship between marijuana initiation and dropping out of high school. Health Econom 9 (1): 9–18

    Google Scholar 

  201. Brook JS, Balka EB, Whiteman M (1999a) The risks for late adolescence of early adolescent marijuana use. Am J Public Health 89 (10): 1549–1554

    Google Scholar 

  202. Brook JS, Cohen P, Brook DW (1998) Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiat 37 (3): 322–330. doi: 10.1097/00004583-199803000-00018

  203. Brook JS, Lee JY, Finch SJ, Koppel J, Brook DW (2011) Psychosocial factors related to cannabis use disorders. Subst Abuse 32 (4): 242–251

    Google Scholar 

  204. Brook JS, Richter L, Whiteman M, Cohen P (1999b) Consequences of adolescent marijuana use: incompatibility with the assumption of adult roles. Genet Social Gen Psychol Monogr 125 (2): 193–207

    Google Scholar 

  205. Brook JS, Whiteman M, Finch SJ, Cohen P (1996) Young adult drug use and delinquency: childhood antecedents and adolescent mediators. J Am Acad Child Adolesc Psychiat 35 (12): 1584–1592. doi: 10.1097/00004583-199612000-00009

  206. Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Schootman M, Cottler LB, Bierut LJ (2011) Number of sexual partners and associations with initiation and intensity of substance use. AIDS Behav 15 (4): 869–874

    Google Scholar 

  207. Coffey C, Patton GC (2016) Cannabis Use in Adolescence and Young Adulthood: A Review of Findings from the Victorian Adolescent Health Cohort Study. Can J Psychiat 61 (6): 318–327. doi: 10.1177/0706743716645289

  208. de Oliveira AM, Buchain PC, Vizzotto ADB, Elkis H, Cordeiro Q (2013) Psychosocial Impact. In: Gellman MD, Turner JR (eds) Encyclopedia of Behavioral Medicine. Springer New York, pp 1583–1584. doi: 10.1007/978-1-4419-1005-9_919

  209. Dornbusch SM, Lin IC, Munroe PT, Bianchi AJ (1999) Adolescent polydrug use and violence in the United States. International journal of adolescent medicine and health 11 (3–4): 197–220. doi: 10.1515/ijamh.1999.11.3-4.197

  210. Edelman NL, de Visser RO, Mercer CH, McCabe L, Cassell JA (2015) Targeting sexual health services in primary care: A systematic review of the psychosocial correlates of adverse sexual health outcomes reported in probability surveys of women of reproductive age. Prevent Med 81: 345–356. doi: http://dx.doi.org/10.1016/j.ypmed.2015.09.019

  211. Eggert LL, Herting JR (1993) Drug involvement among potential dropouts and „typical” youth. J Drug Educn 23 (1): 31–55

    Google Scholar 

  212. Ellickson P, Bui K, Bell R, McGuigan KA (1998) Does early drug use increase the risk of dropping out of high school? J Drug Issue 28 (2): 357–380

    Google Scholar 

  213. Ellickson PL, McGuigan KA (2000) Early predictors of adolescent violence. Am J Public Health 90 (4): 566–572

    Google Scholar 

  214. Ensminger ME, Lamkin RP, Jacobson N (1996) School leaving: a longitudinal perspective including neighborhood effects. Child Dev 67 (5): 2400–2416

    Google Scholar 

  215. Fergusson DM, Boden JM (2008) Cannabis use and later life outcomes. Addiction 103 (6): 969–976; discussion 977–968. doi: 10.1111/j.1360-0443.2008.02221.x

  216. Fergusson DM, Boden JM, Horwood LJ (2015) Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Social p§sychiat Psychiat Epidemiol 50 (9): 1317–1326

    Google Scholar 

  217. Fergusson DM, Horwood LJ (1997) Early onset cannabis use and psychosocial adjustment in young adults. Addiction 92 (3): 279–296

    Google Scholar 

  218. Fergusson DM, Horwood LJ (2000) Does cannabis use encourage other forms of illicit drug use? Addiction 95 (4): 505–520

    Google Scholar 

  219. Fergusson DM, Horwood LJ (2001) The Christchurch Health and Development Study: review of findings on child and adolescent mental health. Aust NZ J Psychiat 35 (3): 287–296

    Google Scholar 

  220. Fergusson DM, Horwood LJ, Beautrais AL (2003a) Cannabis and educational achievement. Addiction 98 (12): 1681–1692

    Google Scholar 

  221. Fergusson DM, Horwood LJ, Swain-Campbell N (2002) Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97 (9): 1123–1135

    Google Scholar 

  222. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003b) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33 (1): 15–21

    Google Scholar 

  223. Fergusson DM, Lynskey MT, Horwood LJ (1996) The short-term consequences of early onset cannabis use. J Abnorm Child Psychol 24 (4): 499–512

    Google Scholar 

  224. Flisher AJ, Chalton DO (1995) High-school dropouts in a working-class South African community: selected characteristics and risk-taking behaviour. J Adolesc 18 (1): 105

    Google Scholar 

  225. Friedman AS, Glassman K, Terras BA (2001) Violent behavior as related to use of marijuana and other drugs. J Addict Dis 20 (1): 49–72. doi: 10.1300/J069v20n01_06

  226. Friedman AS, Kramer S, Kreisher C, Granick S (1996) The relationships of substance abuse to illegal and violent behavior, in a community sample of young adult African American men and women (gender differences). J Subst Abuse 8: 379–402

    Google Scholar 

  227. Gfroerer JC, Greenblatt JC, Wright DA (1997) Substance use in the US college-age population: differences according to educational status and living arrangement. Am J Public Health 87 (1): 62–65

    Google Scholar 

  228. Green KM, Ensminger ME (2006) Adult social behavioral effects of heavy adolescent marijuana use among African Americans. Dev Psychol 42 (6): 1168–1178. doi: 10.1037/0012-1649.42.6.1168

  229. Horwood LJ, Fergusson DM, Hayatbakhsh MR, Najman JM, Coffey C, Patton GC, Silins E, Hutchinson DM (2010) Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend 110 (3): 247–253. doi: http://dx.doi.org/10.1016/j.drugalcdep.2010.03.008

  230. International Narcotics Control Board (2013) Comments on the reported statistics on psychotropic substance for 2012. Vienna

    Google Scholar 

  231. Kaestner R (1994) New Estimates of the Effect of Marijuana and Cocaine Use on Wages. Indust Labor Relat Rev 47 (3): 454–470. doi: 10.2307/2524977

  232. Kandel D (1975) Stages in adolescent involvement in drug use. Science 190 (4217): 912–914

    Google Scholar 

  233. Kandel D, Chen K, Gill A (1995) The Impact of Drug Use on Earnings: A Life-Span Perspective. Social Forces 74 (1): 243–270. doi: 10.2307/2580631

  234. Kandel DB, Yamaguchi K, Chen K (1992) Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol 53 (5): 447–457

    Google Scholar 

  235. Kogan SM, Luo Z, Brody GH, Murry VM (2005) The influence of high school dropout on substance use among African American youth. J Ethnic Substance Abuse 4 (1): 35–51

    Google Scholar 

  236. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895

  237. Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G (2003) A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 98 (5): 685–692

    Google Scholar 

  238. Macleod J, Copello A, Crome I, Smith GD, Egger M, Hickman M, Judd A, Oakes R, Oppenkowski T, Stokes-Lampard H (2005) The psychosocial consequences of drug misuse: A systematic review of longitudinal studies. Drugs Educ Prevent Policy 12 (Suppl 1): 85–89

    Google Scholar 

  239. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Smith GD (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet 363 (9421): 1579–1588. doi: 10.1016/S0140-6736(04)16200-4

  240. McGee R, Williams S, Poulton R, Moffitt T (2000) A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction 95 (4): 491–503

    Google Scholar 

  241. Najman JM, Bor W, O’Callaghan M, Williams GM, Aird R, Shuttlewood G (2005) Cohort profile: the Mater-University of Queensland study of pregnancy (MUSP). Int J Epidemiol 34 (5): 992–997

    Google Scholar 

  242. National Academies of Sciences E, and Medicine. (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press., Washington, DC. doi: 10.17226/24625.

  243. Newcomb MD, Bentler PM (1988) Consequences of adolescent drug use: Impact on the lives of young adults. Sage Publications, Thousand Oaks, Cal

    Google Scholar 

  244. Newcomb MD, Maddahian E, Skager R, Bentler PM (1987) Substance abuse and psychosocial risk factors among teenagers: Associations with sex, age, ethnicity, and type of school. Am J Drug Alcohol Abuse 13 (4): 413–433

    Google Scholar 

  245. OCEBM (2011) The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine, 2 edn. http://www.cebm.net/index.aspx?o = 5653,

  246. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W (2002) Cannabis use and mental health in young people: cohort study. Br Med J 325 (7374): 1195–1198

    Google Scholar 

  247. Patton GC, Harris R, Carlin JB, Hibbert ME, Coffey C, Schwartz M, Bowes G (1997) Adolescent suicidal behaviours: a population-based study of risk. Psychol Med 27 (3): 715–724

    Google Scholar 

  248. Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, Lengerich

    Google Scholar 

  249. Roebuck MC, French MT, Dennis ML (2004) Adolescent marijuana use and school attendance. Econom Educ Rev 23 (2): 133–141

    Google Scholar 

  250. Scheier LM, Botvin GJ (1995) Effects of early adolescent drug use on cognitive efficacy in early-late adolescence: a developmental structural model. J Subst Abuse 7 (4): 379–404

    Google Scholar 

  251. Schlossarek S, Kempkensteffen J, Reimer J, Verthein U (2016) Psychosocial Determinants of Cannabis Dependence: A Systematic Review of the Literature. Eur Addict Res 22 (3): 131–144

    Google Scholar 

  252. SIGN (2015) Scottish Intercollegiate Guidelines Network, SIGN 50 Methodology checklist. Edinburgh, United Kingdom

    Google Scholar 

  253. Stenbacka M, Allebeck P, Brandt L, Romelsjo A (1992) Intravenous drug abuse in young men: risk factors assessed in a longitudinal perspective. Scand J Soc Med 20 (2): 94–101

    Google Scholar 

  254. Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC (2008) Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. Addiction 103 (8): 1361–1370

    Google Scholar 

  255. Townsend L, Flisher AJ, King G (2007) A systematic review of the relationship between high school dropout and substance use. Clin Child Family Psychol Rev 10 (4): 295–372. doi: 10.1007/s10567-007-0023-7

  256. Van den Bree MB, Pickworth WB (2005) Risk factors predicting changes in marijuana involvement in teenagers. Arch Gen Psychiat 62 (3): 311–319

    Google Scholar 

  257. White HR, Loeber R, Stouthamer-Loeber M, Farrington DP (1999) Developmental associations between substance use and violence. Dev Pychopathol 11 (4): 785–803

    Google Scholar 

  258. Windle M (1997) Mate similarity, heavy substance use and family history of problem drinking among young adult women. J Stud Alcohol 58 (6): 573–580

    Google Scholar 

  259. Zimmerman MA, Maton KI (1992) Life-style and substance use among male African American urban adolescents: A cluster analytic approach. Am J Community Psychol 20 (1): 121–138

    Google Scholar 

  260. Anderson BM, Rizzo M, Block RI, Pearlson GD, O’Leary DS (2010) Sex differences in the effects of marijuana on simulated driving performance. J Psychoact Drugs 42 (1): 19–30. doi: 10.1080/02791072.2010.10399782

  261. Asbridge M, Hayden JA, Cartwright JL (2012) Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. Br Med J 344: e536. doi: 10.1136/bmj.e536

  262. Asbridge M, Poulin C, Donato A (2005) Motor vehicle collision risk and driving under the influence of cannabis: evidence from adolescents in Atlantic Canada. Accid Anal Prevent 37 (6): 1025–1034. doi: 10.1016/j.aap.2005.05.006

  263. Baldock M (2007) Review of the literature on cannabis and crash risk. Centre for Automotive Safety Research, University of Adelade, Australia

    Google Scholar 

  264. Blows S, Ivers RQ, Connor J, Ameratunga S, Woodward M, Norton R (2005) Marijuana use and car crash injury. Addiction 100 (5): 605–611. doi: 10.1111/j.1360-0443.2005.01100.x

  265. Brault M, Dussault, C, Bouchard, J, Lemire, AM (2004) The contribution of alcohol and other drugs among fatally injured drivers in Quebec: final results. Paper presented at the 17th International Conference on Alcohol, Drugs and Traffic Safety Glasgow, United Kingdom, August 8–13, 2004

    Google Scholar 

  266. Chait LD, Perry JL (1994) Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology 115 (3): 340–349

    Google Scholar 

  267. Drummer O (1995) A review of the contribution of drugs in drivers to road accidents. Government Printer, Melbourne

    Google Scholar 

  268. Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, Swann P (2004) The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prevent 36 (2): 239–248

    Google Scholar 

  269. Elvik R (2013) Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies. Accident Anal Prevent 60: 254–267. doi: 10.1016/j.aap.2012.06.017

  270. EMCDDA (2014) Drug use, impaired driving and traffic accidents. Insights, 2nd edn. Lisbon

    Google Scholar 

  271. Fergusson DM, Horwood LJ (2001) Cannabis use and traffic accidents in a birth cohort of young adults. Accid Anal Prevent 33 (6): 703–711

    Google Scholar 

  272. Girotto E, Mesas AE, de Andrade SM, Birolim MM (2014) Psychoactive substance use by truck drivers: a systematic review. Occupat Environ Med 71 (1): 71–76. doi: 10.1136/oemed-2013-101452

  273. Hartman RL, Huestis MA (2013) Cannabis effects on driving skills. Clin Chem 59 (3): 478–492. doi: 10.1373/clinchem.2012.194381

  274. Lamers CT, Ramaekers JG (2001) Visual search and urban driving under the influence of marijuana and alcohol. Human Psychopharmacol 16 (5): 393–401. doi: 10.1002/hup.307

  275. Laumon B, Gadegbeku B, Martin JL, Biecheler MB, Group SAM (2005) Cannabis intoxication and fatal road crashes in France: population based case-control study. Br Med J 331 (7529): 1371. doi: 10.1136/bmj.38648.617986.1F

  276. Lenne MG, Dietze PM, Triggs TJ, Walmsley S, Murphy B, Redman JR (2010) The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. Accid Anal Prevent 42 (3): 859–866. doi: 10.1016/j.aap.2009.04.021

  277. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895

  278. Li M-C, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G (2012) Marijuana use and motor vehicle crashes. Epidemiol Rev 34 (1): 65–72

    Google Scholar 

  279. Liguori A, Gatto CP, Jarrett DB (2002) Separate and combined effects of marijuana and alcohol on mood, equilibrium and simulated driving. Psychopharmacology 163 (3–4): 399–405. doi: 10.1007/s00213-002-1124-0

  280. Liguori A, Gatto CP, Robinson JH (1998) Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. Behav Pharmacol 9 (7): 599–609

    Google Scholar 

  281. Longo MC, Hunter CE, Lokan RJ, White JM, White MA (2000) The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part ii: the relationship between drug prevalence and drug concentration, and driver culpability. Accident Anal Prevent 32 (5): 623–632

    Google Scholar 

  282. McCabe SE, Cranford JA, Morales M, Young A (2006) Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences. J Stud Alcohol 67 (4): 529–537

    Google Scholar 

  283. McDonald J, Schleifer L, Richards JB, de Wit H (2003) Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28 (7): 1356–1365. doi: 10.1038/sj.npp.1300176

  284. Menetrey A, Augsburger M, Favrat B, Pin MA, Rothuizen LE, Appenzeller M, Buclin T, Mangin P, Giroud C (2005) Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC. J Anal Toxicol 29 (5): 327–338

    Google Scholar 

  285. Mura P, Kintz P, Ludes B, Gaulier JM, Marquet P, Martin-Dupont S, Vincent F, Kaddour A, Goulle JP, Nouveau J, Moulsma M, Tilhet-Coartet S, Pourrat O (2003) Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. Forensic Sci Int 133 (1–2): 79–85

    Google Scholar 

  286. Musshoff F, Madea B (2006) Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monitoring 28 (2): 155–163. doi: 10.1097/01.ftd.0000197091.07807.22

  287. OCEBM (2011) Levels of Evidence Working Group, The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford

  288. Papafotiou K, Carter JD, Stough C (2005) The relationship between performance on the standardised field sobriety tests, driving performance and the level of Delta9-tetrahydrocannabinol (THC) in blood. Forensic Sci Int 155 (2–3): 172–178. doi: 10.1016/j.forsciint.2004.11.009

  289. Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch: eine Expertise zu gesundheitlichen und psychosozialen Folgen; ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publ., Lengerich

    Google Scholar 

  290. Peterson J, Welch V, Losos M, Tugwell P (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp]

  291. Rafaelsen OJ, Bech P, Christiansen J, Christrup H, Nyboe J, Rafaelsen L (1973a) Cannabis and alcohol: effects on stimulated car driving. Science 179 (4076): 920–923

    Google Scholar 

  292. Rafaelsen OJ, Bech P, Rafaelsen L (1973b) Simulated car driving influenced by cannabis and alcohol. Pharmakopsychiatr Neuropsychopharmakol 6 (2): 71–83. doi: 10.1055/s-0028-1094370

  293. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31 (10): 2296–2303. doi: 10.1038/sj.npp.1301068

  294. Ramaekers JG, Robbe HW, O’Hanlon JF (2000) Marijuana, alcohol and actual driving performance. Human Psychopharmacol 15 (7): 551–558. doi: 10.1002/1099-1077(200010)15:7<551:AID-HUP236>3.0.CO;2-P

  295. Robbe H (1998) Marijuana’s impairing effects on driving are moderate when taken alone but severe when combined with alcohol. Human Psychopharmacol Clin Exp 13 (S2): S70-S78

    Google Scholar 

  296. Robbe H, O’Hanlon, JF (1999) Marijuana, alcohol and actual driving performance. Washington, DC

    Google Scholar 

  297. Ronen A, Chassidim HS, Gershon P, Parmet Y, Rabinovich A, Bar-Hamburger R, Cassuto Y, Shinar D (2010) The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prevent 42 (6): 1855–1865. doi: 10.1016/j.aap.2010.05.006

  298. Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, Cassuto Y, Shinar D (2008) Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prevent 40 (3): 926–934. doi: 10.1016/j.aap.2007.10.011

  299. Senna MC, Augsburger M, Aebi B, Briellmann TA, Donze N, Dubugnon JL, Iten PX, Staub C, Sturm W, Sutter K (2010) First nationwide study on driving under the influence of drugs in Switzerland. Forensic Sci Int 198 (1–3): 11–16. doi: 10.1016/j.forsciint.2010.02.014

  300. Smiley A (1999) Marijuana: on-road and driving simulator studies. In: Kalant H CW, Hall W, Smart RG (ed) The health effects of cannabis. Centre for Addiction and Mental Health, Toronto, pp 173–191

    Google Scholar 

  301. Terhune K, Ippolito C, Hendricks D, Michalovic J, Bogema S, Santinga P, Blomberg R, Preusser D (1992) The incidence and role of drugs in fatally injured drivers. Final report. [https://catalog.hathitrust.org/Record/005516221]

  302. Walsh JM, Flegel R, Atkins R, Cangianelli LA, Cooper C, Welsh C, Kerns TJ (2005) Drug and alcohol use among drivers admitted to a Level-1 trauma center. Accid Anal Prevent 37 (5): 894–901. doi: 10.1016/j.aap.2005.04.013

  303. Walsh JM, Flegel R, Cangianelli LA, Atkins R, Soderstrom CA, Kerns TJ (2004) Epidemiology of alcohol and other drug use among motor vehicle crash victims admitted to a trauma center. Traffic Inj Prevent 5 (3): 254–260. doi: 10.1080/15389580490465319

  304. Woratanarat P, Ingsathit A, Suriyawongpaisal P, Rattanasiri S, Chatchaipun P, Wattayakorn K, Anukarahanonta T (2009) Alcohol, illicit and non-illicit psychoactive drug use and road traffic injury in Thailand: a case-control study. Accid Anal Prevent 41 (3): 651–657. doi: 10.1016/j.aap.2009.03.002

  305. Abrantes AM, Lee CS, MacPherson L, Strong DR, Borrelli B, Brown RA (2009) Health risk behaviors in relation to making a smoking quit attempt among adolescents. J Behav Med 32 (2): 142–149. doi: 10.1007/s10865-008-9184-1

  306. Agrawal A, Lynskey MT (2009) Tobacco and cannabis co-occurrence: does route of administration matter? Drug Alcohol Depend 99 (1–3): 240–247. doi: 10.1016/j.drugalcdep.2008.08.007

  307. Agrawal A, Lynskey MT, Kapoor M, Bucholz KK, Edenberg HJ, Schuckit M, Brooks A, Hesselbrock V, Kramer J, Saccone N, Tischfield J, Bierut LJ (2015) Are genetic variants for tobacco smoking associated with cannabis involvement? Drug Alcohol Depend 150: 183–187. doi: 10.1016/j.drugalcdep.2015.02.029

  308. Agrawal A, Lynskey MT, Madden PA, Pergadia ML, Bucholz KK, Heath AC (2009) Simultaneous cannabis and tobacco use and cannabis-related outcomes in young women. Drug Alcohol Depend 101 (1–2): 8–12. doi: 10.1016/j.drugalcdep.2008.10.019

  309. Agrawal A, Madden PA, Bucholz KK, Heath AC, Lynskey MT (2008a) Transitions to regular smoking and to nicotine dependence in women using cannabis. Drug Alcohol Depend 95 (1–2): 107–114. doi: 10.1016/j.drugalcdep.2007.12.017

  310. Agrawal A, Pergadia ML, Lynskey MT (2008b) Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions? Am J Addict 17 (3): 199–208. doi: 10.1080/10550490802019519

  311. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, Arlington, VA

    Google Scholar 

  312. APA APA (American Psychiatric Association) (ed) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC

    Google Scholar 

  313. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P (2007) Psychopathology among cannabis-dependent treatment seekers and association with later substance abuse treatment. J Subst Abuse Treat 32 (2): 113–119. doi: 10.1016/j.jsat.2006.07.005

  314. Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiat 184 (2): 110–117

    Google Scholar 

  315. Baek JH, Zheng Y, Darlington CL, Smith PF (2008) Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 128 (9): 961–967. doi: 10.1080/00016480701796944

  316. Behrendt S, Beesdo-Baum K, Hofler M, Perkonigg A, Buhringer G, Lieb R, Wittchen HU (2012) The relevance of age at first alcohol and nicotine use for initiation of cannabis use and progression to cannabis use disorders. Drug Alcohol Depend 123 (1–3): 48–56. doi: 10.1016/j.drugalcdep.2011.10.013

  317. Behrendt S, Wittchen HU, Höfler M, Lieb R, Beesdo K (2009) Transitions from first substance use to substance use disorders in adolescence: Is early onset associated with a rapid escalation? Drug Alcohol Depend 99 (1): 68–78. doi: https://doi.org/10.1016/j.drugalcdep.2008.06.014

  318. Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs MO (2011) CNR1 gene polymorphisms in addictive disorders: A systematic review and a meta-analysis. Addict Biol 16 (1): 1–6. doi: 10.1111/j.1369-1600.2009.00198.x

  319. Blanco C, Hasin DS, Wall MM, Florez-Salamanca L, Hoertel N, Wang S, Kerridge BT, Olfson M (2016) Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. JAMA Psychiat 73 (4): 388–395. doi: 10.1001/jamapsychiatry.2015.3229

  320. Boden JM, Fergusson DM, Horwood LJ (2006) Illicit drug use and dependence in a New Zealand birth cohort. Aust NZ J Psychiatry 40 (2): 156–163. doi: 10.1080/j.1440-1614.2006.01763.x

  321. Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO (2013) Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict 22 (3): 277–284. doi: 10.1111/j.1521-0391.2012.12018.x

  322. Bonnet U, Preuss UW (2017) The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 8: 9–37. doi: 10.2147/SAR.S109576

  323. Budney AJ, Hughes JR (2006) The cannabis withdrawal syndrome. Curr Opin Psychiat 19 (3): 233–238. doi: 10.1097/01.yco.0000218592.00689.e5

  324. Bühler KM, Giné E, Echeverry-Alzate V, Calleja-Conde J, de Fonseca FR, López-Moreno JA (2015) Common single nucleotide variants underlying drug addiction: More than a decade of research. Addict Biol 20 (5): 845–871. doi: 10.1111/adb.12204

  325. BZgA (2015) Der Cannabiskonsum Jugendlicher und junger Erwachsener in Deutschland 2014. Ergebnisse einer aktuellen Repräsentativbefragung und Trends. Bundeszentrale für gesundheitliche Aufklärung. Köln

    Google Scholar 

  326. Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, Callaghan B, Rana U, McLaren J (2010a) Systematic review of prospective studies investigating „remission” from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav 35 (8): 741–749. doi: 10.1016/j.addbeh.2010.03.019

  327. Calabria B, Degenhardt L, Hall W, Lynskey M (2010b) Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 29 (3): 318–330

    Google Scholar 

  328. Chen C-Y, O’Brien MS, Anthony JC (2005) Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug Alcohol Depend 79 (1): 11–22. doi: 10.1016/j.drugalcdep.2004.11.014

  329. Coffey C, Carlin JB, Lynskey M, Li N, Patton GC (2003) Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study. Br J Psychiat 182: 330–336

    Google Scholar 

  330. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004) Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA 291 (17): 2114–2121. doi: 10.1001/jama.291.17.2114

  331. Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ (2015) Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiat Res 66–67: 135–141. doi: 10.1016/j.jpsychires.2015.05.004

  332. Cougle JR, Hakes JK, Macatee RJ, Zvolensky MJ, Chavarria J (2016) Probability and correlates of dependence among regular users of alcohol, nicotine, cannabis, and cocaine: concurrent and prospective analyses of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiat 77 (4): e444–450. doi: 10.4088/JCP.14m09469

  333. de Dios MA, Vaughan EL, Stanton CA, Niaura R (2009) Adolescent tobacco use and substance abuse treatment outcomes. J Subst Abuse Treat 37 (1): 17–24. doi: 10.1016/j.jsat.2008.09.006

  334. Degenhardt L, Hall W (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet 379 (9810): 55–70. doi: 10.1016/S0140-6736(11)61138-0

  335. Degenhardt L, Bucello C, Calabria B, Nelson P, Roberts A, Hall W, Lynskey M, Wiessing L (2011) What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 117 (2–3): 85–101. doi: 10.1016/j.drugalcdep.2010.11.032

  336. Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC (2010) Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiat 196 (4): 290–295. doi: 10.1192/bjp.bp.108.056952

  337. Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T (2013a) The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. PloS one 8 (10) (no pagination) (e76635). doi: http://dx.doi.org/10.1371/journal.pone.0076635

  338. Degenhardt L, Hall W (2001) The relationship between tobacco use, substance-use disorders and mental health: results from the National Survey of Mental Health and Well-being. Nicotine Tobacco Res 3 (3): 225–234. doi: 10.1080/14622200110050457

  339. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A, Murray CJL, Vos T (2013b) Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. Lancet 382 (9904): 1564–1574. doi: 10.1016/S0140-6736(13)61530-5

  340. Dilling H, Mombour W, Schmidt MH (1992) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Klinisch-diagnostiche Leitlinien. 7. Aufl. World Health Organization, Geneva

    Google Scholar 

  341. EMCDDA (2017) European Monitoring Centre for Drugs and Drug Addiction. European drug report: trends and developments [http://www.emcdda.europa.eu/publications/edr/trends-developments/2017_en]

  342. Farmer RF, Kosty DB, Seeley JR, Duncan SC, Lynskey MT, Rohde P, Klein DN, Lewinsohn PM (2015) Natural course of cannabis use disorders. Psychol Med 45 (1): 63–72. doi: 10.1017/s003329171400107X

  343. Feingold D, Weiser M, Rehm J, Lev-Ran S (2016) The association between cannabis use and anxiety disorders: Results from a population-based representative sample. Eur Neuropsychopharmacol 26 (3): 493–505. doi: 10.1016/j.euroneuro.2015.12.037

  344. Ford DE, Vu HT, Anthony JC (2002) Marijuana use and cessation of tobacco smoking in adults from a community sample. Drug Alcohol Depend 67 (3): 243–248

    Google Scholar 

  345. Gomes de Matos E, Atzendorf J, Kraus L, Piontek D (2016) Substanzkonsum in der Allgemeinbevölkerung in Deutschland. Ergebnisse des Epidemiologischen Suchtsurveys 2015. Sucht 62 (5): 271–281

    Google Scholar 

  346. Gossop M, Darke S, Griffiths P, Hando J., Powis B., Hall W, Strang J (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90 (5): 607–614

    Google Scholar 

  347. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ (1994) Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. Br Med J 309 (6958): 842–846

    Google Scholar 

  348. Grant JD, Scherrer JF, Neuman RJ, Todorov AA, Price RK, Bucholz KK (2006) A comparison of the latent class structure of cannabis problems among adult men and women who have used cannabis repeatedly. Addiction 101 (8): 1133–1142. doi: 10.1111/j.1360-0443.2006.01463.x

  349. Gray KM, Riggs PD, Min SJ, Mikulich-Gilbertson SK, Bandyopadhyay D, Winhusen T (2011) Cigarette and cannabis use trajectories among adolescents in treatment for attention-deficit/hyperactivity disorder and substance use disorders. Drug Alcohol Depend 117 (2–3): 242–247. doi: 10.1016/j.drugalcdep.2011.02.005

  350. Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ (2014a) Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend 136: 158–161. doi: 10.1016/j.drugalcdep.2013.11.022

  351. Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ (2014b) Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend 136: 158–161. doi: 10.1016/j.drugalcdep.2013.11.022

  352. Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374 (9698): 1383–1391

    Google Scholar 

  353. Hall W, Degenhardt L, Lynskey M (2001) The health and psychological consequences of cannabis use. Australian Publishing Service, Canberra

    Google Scholar 

  354. Hartz SM, Pato CN, Medeiros H, et al. (2014) Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiat 71 (3): 248–254. doi: 10.1001/jamapsychiatry.2013.3726

  355. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF (2015) Prevalence of Marijuana Use Disorders in the United States Between 2001–2002 and 2012–2013. JAMA Psychiat 72 (12): 1235–1242. doi: 10.1001/jamapsychiatry.2015.1858

  356. Haskins A, Bertone-Johnson E, Pekow P, Carbone E, Chasan-Taber L (2010) Correlates of smoking cessation at pregnancy onset among Hispanic women in Massachusetts. American journal of health promotion: AJHP 25 (2): 100–108. doi: 10.4278/ajhp.090223-QUAN-77

  357. Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, O’Callaghan MJ, Williams GM (2009) Childhood sexual abuse and cannabis use in early adulthood: findings from an Australian birth cohort study. Arch Sex Beh 38 (1): 135–142. doi: 10.1007/s10508-007-9172-5

  358. Hoch E, Petersen K, Thomasius R (2016) Cannabis. In: Batra A, Bilke-Hentsch O (eds) Praxisbuch Sucht. Therapie der Suchterkrankungen im Jugend- und Erwachsenenalter. Thieme, Stuttgart New York

    Google Scholar 

  359. Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4 (8): 1770–1804. doi: 10.1002/cbdv.200790152

  360. Humfleet G, Munoz R, Sees K, Reus V, Hall S (1999) History of alcohol or drug problems, current use of alcohol or marijuana, and success in quitting smoking. Addict Behav 24 (1): 149–154

    Google Scholar 

  361. Humphreys KL, Eng T, Lee SS (2013) Stimulant medication and substance use outcomes: A meta-analysis. JAMA Psychiat 70 (7): 740–749. doi: 10.1001/jamapsychiatry.2013.1273

  362. Iversen L (2003) Cannabis and the brain. Brain 126 (Pt 6): 1252–1270

    Google Scholar 

  363. Kandel D (1975) Stages in adolescent involvement in drug use. Science 190 (4217): 912–914

    Google Scholar 

  364. Kandel D, Faust R (1975) Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiat 32 (7): 923–932

    Google Scholar 

  365. Kedzior KK, Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- A meta-analysis of 31 studies. BMC Psychiat 14. doi: 10.1186/1471-244X-14-136

  366. Kelly E, Darke S, Ross J (2004) A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 23 (3): 319–344

    Google Scholar 

  367. Kraus L, Pabst A, Gomes de Matos E, Piontek D (2014) Kurzbericht Epidemiologischer Suchtsurvey 2012. Tabellenband: Prävalenz des Konsums illegaler Drogen, multipler Drogenerfahrung und drogenbezogener Störungen nach Geschlecht und Alter im Jahr 2012. IFT Institut für Therapieforschung, München

    Google Scholar 

  368. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895

  369. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Smith GD (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet 363 (9421): 1579–1588. doi: 10.1016/S0140-6736(04)16200-4

  370. Metrik J, Spillane NS, Leventhal AM, Kahler CW (2011) Marijuana use and tobacco smoking cessation among heavy alcohol drinkers. Drug Alcohol Depend 119 (3): 194–200. doi: 10.1016/j.drugalcdep.2011.06.004

  371. Montanari L, Guarita B, Mounteney J, Zipfel N, Simon R (2017) Cannabis Use among People Entering Drug Treatment in Europe: A Growing Phenomenon? Eur Addict Res 23 (3): 113–121

    Google Scholar 

  372. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (9584): 319–328. doi: http://dx.doi.org/10.1016/S0140-6736%2807%2961162-3

  373. National Academies of Sciences E, and Medicine. (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. The National Academies Press, Washington, DC. doi: 10.17226/24625.

  374. Newcomb MD, Galaif ER, Locke TF (2001) Substance use diagnoses within a community sample of adults: Distinction, comorbidity, and progression over time. Profess Psychol Res Pract 32 (3): 239

    Google Scholar 

  375. OCEBM (2011) Levels of Evidence Working Group. The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford

  376. Pacek LR, Martins SS, Crum RM (2013) The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: Results from a national sample. J Affect Disord 148 (2–3): 188–195. doi: http://dx.doi.org/10.1016/j.jad.2012.11.059

  377. Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M (2005) Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100 (10): 1518–1525. doi: 10.1111/j.1360-0443.2005.01220.x

  378. Patton GC, Coffey C, Carlin JB, Sawyer SM, Wakefield M (2006) Teen smokers reach their mid twenties. J Adolesc Health 39 (2): 214–220. doi: 10.1016/j.jadohealth.2005.11.027

  379. Peer K, Rennert L, Lynch KG, Farrer L, Gelernter J, Kranzler HR (2013) Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. Drug Alcohol Depend 127 (1): 215–219

    Google Scholar 

  380. Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen HU (2008) The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 103 (3): 439–449

    Google Scholar 

  381. Peters EN, Budney AJ, Carroll KM (2012) Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction 107 (8): 1404–1417. doi: http://dx.doi.org/10.1111/j.1360-0443.2012.03843.x

  382. Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, Lengerich

    Google Scholar 

  383. Pingault JB, Cote SM, Galera C, Genolini C, Falissard B, Vitaro F, Tremblay RE (2013) Childhood trajectories of inattention, hyperactivity and oppositional behaviors and prediction of substance abuse/dependence: a 15-year longitudinal population-based study. Mol Psychiat 18 (7): 806–812. doi: 10.1038/mp.2012.87

  384. Ramesh D, Schlosburg JE, Wiebelhaus JM, Lichtman AH (2011) Marijuana Dependence: Not Just Smoke and Mirrors. ILAR journal/National Research Council, Institute of Laboratory Animal Resources 52 (3): 295–308. doi: 10.1093/ilar.52.3.295

  385. Rummel C, Budde A, Schulte L, Dammer E, Karachaliou K, Pfeiffer-Gerschel T (2016) 2016 National report (2015 data) to the EMCDDA by the REITOX National Focal Point. Germany, Workbook Treatment. Deutsche Beobachtungsstelle für Drogen und Drogensucht DBDD., Munich

    Google Scholar 

  386. Schwantes-An T-H, Zhang J, Chen L-S, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen P-H, Yang B-Z, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, Kranzler HR, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Müller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nöthen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerström N, Scherbaum N, Schmäl C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, Hopfer CJ, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PAF, McGue M, Munafò MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL (2015) Association of the oprm1 variant rs1799971 (a118g) with non-specific liability to substance dependence in a collaborative de novo meta-analysis of european-ancestry cohorts. Behav Genet. doi: 10.1007/s10519-015-9737-3

  387. Sharma P, Murthy P, Bharath MM (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiat 7 (4): 149–156

    Google Scholar 

  388. SIGN (2015) Scottish Intercollegiate Guidelines Network, SIGN 50 Methodology Checklist. Edinburgh, United Kingdom

    Google Scholar 

  389. Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, Toumbourou JW, Degenhardt L, Swift W, Coffey C, Tait RJ, Letcher P, Copeland J, Mattick RP (2014) Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiat 1 (4): 286–293. doi: https://doi.org/10.1016/S2215-0366(14)70307-4

  390. Smith-Kielland A, Skuterud B, Morland J (1999) Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 23 (5): 323–332

    Google Scholar 

  391. Stapleton JA, Keaney F, Sutherland G (2009) Illicit drug use as a predictor of smoking cessation treatment outcome. Nicotine Tobacco Res 11 (6): 685–689. doi: 10.1093/ntr/ntp050

  392. Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC (2008) Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. Addiction (Abingdon, England) 103 (8): 1361–1370. doi: 10.1111/j.1360-0443.2008.02246.x

  393. Timberlake DS (2009) A comparison of drug use and dependence between blunt smokers and other cannabis users. Subst Use Misuse 44 (3): 401–415. doi: 10.1080/10826080802347651

  394. Timberlake DS, Haberstick BC, Hopfer CJ, Bricker J, Sakai JT, Lessem JM, Hewitt JK (2007) Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents. Drug Alcohol Depend 88 (2–3): 272–281. doi: 10.1016/j.drugalcdep.2006.11.005

  395. United Nations Office on Drugs and Crime (2017) World drug report. United Nations Office on Drugs and Crime, Vienna, Austria

    Google Scholar 

  396. Walsh K, Elliott JC, Shmulewitz D, Aharonovich E, Strous R, Frisch A, Weizman A, Spivak B, Grant BF, Hasin D (2014) Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel. Comprehens Psychiat 55 (3): 621–630. doi: 10.1016/j.comppsych.2013.11.016

  397. Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, Lieb R, Perkonigg A (2007) Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 88 Suppl 1: S60–70. doi: 10.1016/j.drugalcdep.2006.12.013

  398. Wong A, Montebello ME, Norberg MM, Rooney K, Lintzeris N, Bruno R, Booth J, Arnold JC, McGregor IS (2013) Exercise increases plasma THC concentrations in regular cannabis users. Drug Alcohol Depend 133 (2): 763–767. doi: 10.1016/j.drugalcdep.2013.07.031

  399. APA – American Psychiatric Association (ed) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC

    Google Scholar 

  400. Baldacchino A, Hughes Z, Kehoe M, Blair H, Teh Y, Windeatt S, Crome IB (2012) Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review. Am J Addict 21 Suppl 1: S88–98. doi: 10.1111/j.1521-0391.2012.00295.x

  401. Ben Amar M, Potvin S (2007) Cannabis and psychosis: what is the link? J Psychoact Drugs 39 (2): 131–142

    Google Scholar 

  402. Burns JK (2012) Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis. Curr Pharm Des 18 (32): 5093–5104

    Google Scholar 

  403. Cookey J, Bernier D, Tibbo PG (2014) White matter changes in early phase schizophrenia and cannabis use: An update and systematic review of diffusion tensor imaging studies. Schizophrenia Research 156 (2–3): 137–142. doi: http://dx.doi.org/10.1016/j.schres.2014.04.026

  404. Elm E, Altman D, Egger M, Pocock S, Gøtzsche P, Vandenbroucke J (2008) The Strengthening the Reporting of Observational Studies in Epidemiology[STROBE] statement: guidelines for reporting observational studies. Gaceta Sanitaria 22: 144–150.

    Google Scholar 

  405. Ferretjans R, Moreira FA, Teixeira AL, Salgado JV (2012) The endocannabinoid system and its role in schizophrenia: A systematic review of the literature. Rev Bras Psiquiat 34 (Suppl 2): S163-S193. doi: 10.1016/j.rbp.2012.07.003

  406. Geoffroy PA, Etain B, Houenou J (2013) Gene x environment interactions in schizophrenia and bipolar disorder: Evidence from neuroimaging. Front Psychiat 14,4: 136

    Google Scholar 

  407. Goes FS (2016) Genetics of Bipolar Disorder: Recent Update and Future Directions. Psychiat Clin N Am 39 (1): 139–155. doi: 10.1016/j.psc.2015.10.004

  408. Jacobi F, Höfler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Maske U, Hapke U, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen H-U (2014) Psychische Störungen in der Allgemeinbevölkerung. Nervenarzt 85: 77–87

    Google Scholar 

  409. James A, James C, Thwaites T (2013) The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiat Res 214 (3): 181–189. doi: http://dx.doi.org/10.1016/j.pscychresns.2013.07.012

  410. Janzarik W (2003) Der Psychose-Begriff und die Qualität des Psychotischen. Nervenarzt 74 (1): 3–11. doi: https://doi.org/10.1007/s00115–002–1348–6

  411. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophren Bull 36 (6): 1115–1130. doi: http://dx.doi.org/10.1093/schbul/sbp031

  412. Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, de Haan L, van der Gaag M (2015) Cannabis use and transition to psychosis in individuals at ultra-high risk: Review and meta-analysis. Psychol Med 46, 4: 673–681 doi: 10.1017/S0033291715002329

  413. Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011) Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Arch Gen Psychiat 68 (6): 555–561. doi: http://dx.doi.org/10.1001/archgenpsychiatry.2011.5

  414. Leweke FM, Koethe D (2008) Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 13 (2): 264–275. doi: 10.1111/j.1369-1600.2008.00106.x

  415. Linscott RJ, van Os J (2013) An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: On the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 43 (6): 1133–1149

    Google Scholar 

  416. Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T (2013) Cannabis abuse and brain morphology in schizophrenia: A review of the available evidence. Eur Arch Psychiat Clin Neurosci 263 (1): 3–13. doi: http://dx.doi.org/10.1007/s00406-012-0346-3

  417. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bul. doi: 10.1093/schbul/sbw003

  418. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (9584): 319–328. doi: http://dx.doi.org/10.1016/S0140-6736%2807%2961162-3

  419. Myles H, Myles N, Large M (2016) Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust NZ J Psychiat 50 (3): 208–219. doi: 10.1177/0004867415599846

  420. Myles N, Newall H, Nielssen O, Large M (2012) The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des 18 (32): 5055–5069

    Google Scholar 

  421. Network SIG (2015) SIGN 50: a guideline developer’s handbook. SIGN, Edinburgh

    Google Scholar 

  422. OCEBM LoEWG (2011) The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine, Oxford

    Google Scholar 

  423. Peters UH (2011) Lexikon. Psychiatrie, Psychotherapie, medizinische Psychologie. Elsevier. Urban & Fischer, München

    Google Scholar 

  424. Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und -missbrauch. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. 1 systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, Lengerich

    Google Scholar 

  425. Potvin S, Sepehry AA, Stip E (2006) A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 36 (4): 431–440. doi: 10.1017/S003329170500574X

  426. Potvin S, Sepehry AA, Stip E (2007) Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust NZ J Psychiat 41 (10): 792–799. doi: 10.1080/00048670701579041

  427. Rapp C, Bugra H, Riecher-Rossler A, Tamagni C, Borgwardt S (2012) Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des 18 (32): 5070–5080

    Google Scholar 

  428. Sara GE, Large MM, Matheson SL, Burgess PM, Malhi GS, Whiteford HA, Hall WD (2015) Stimulant use disorders in people with psychosis: A meta-analysis of rate and factors affecting variation. Aust NZ J Psychiat 49 (2): 106–117. doi: 10.1177/0004867414561526

  429. Schoeler T, Monk A (2016).

    Google Scholar 

  430. Semple DM, McIntosh AM, Lawrie SM (2005) Cannabis as a risk factor for psychosis: Systematic review. J Psychopharmacol 19 (2): 187–194. doi: 10.1177/0269881105049040

  431. Serafini G, Pompili M, Innamorati M, Rihmer Z, Sher L, Girardi P (2012) Can cannabis increase the suicide risk in psychosis? A critical review. Curr Pharm Des 18 (32): 5165–5187

    Google Scholar 

  432. Szoke A, Galliot AM, Richard JR, Ferchiou A, Baudin G, Leboyer M, Schurhoff F (2014) Association between cannabis use and schizotypal dimensions – A meta-analysis of cross-sectional studies. Psychiat Res 219 (1): 58–66. doi: http://dx.doi.org/10.1016/j.psychres.2014.05.008

  433. Uliana V, Tomassini A, Pollice R, Gennarelli M, Faravelli F, Casacchia M, Di Maria E (2013) Cannabis and psychosis: A systematic review of genetic studies. Curr Psychiat Rev 9 (4): 302–315

    Google Scholar 

  434. Zammit S, Moore THM, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2008) Effects of cannabis use on outcomes of psychotic disorders: Systematic review. Br J Psychiat 193 (5): 357–363. doi: http://dx.doi.org/10.1192/bjp.bp.107.046375

  435. Zondervan KT (2011) Genetic Association Study Design. In: Zeggini E, Morris A (eds) Analysis of Complex Disease Association Studies. Elsevir, Burlington, MA, USA, pp 25–47

    Google Scholar 

  436. APA (American Psychiatric Association) (ed) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC

    Google Scholar 

  437. Baggio S, N’Goran AA, Deline S, Studer J, Dupuis M, Henchoz Y, Mohler-Kuo M, Daeppen JB, Gmel G (2014) Patterns of cannabis use and prospective associations with health issues among young males. Addiction 109 (6): 937–945. doi: 10.1111/add.12490

  438. Borowsky IW, Ireland M, Resnick MD (2001) Adolescent suicide attempts: risks and protectors. Pediatrics 107: 485–493

    Google Scholar 

  439. Brook J, Rosen Z, Brook D (2001) The effect of early marijuana use on later anxiety and depressive symptoms. NYS Psychologist (New York): 35–40

    Google Scholar 

  440. Brook JS, Cohen P, Brook DW (1998) Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiat 37: 322–330

    Google Scholar 

  441. Cairns KE, Yap MBH, Pilkington PD, Jorm AF (2014) Risk and protective factors for depression that adolescents can modify: A systematic review and meta-analysis of longitudinal studies. J Affect Disord 169: 61–75. doi: 10.1016/j.jad.2014.08.006

  442. Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ (2015) Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiat Res 66–67: 135–141. doi: 10.1016/j.jpsychires.2015.05.004

  443. Danielsson A-K, Lundin A, Agardh E, Allebeck P, Forsell Y (2016) Cannabis use, depression and anxiety: A 3-year prospective population-based study. J Affect Disord 193: 103–108. doi: 10.1016/j.jad.2015.12.045

  444. Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC (2013) The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction (Abingdon, England) 108 (1): 124–133. doi: http://dx.doi.org/10.1111/j.1360-0443.2012.04015.x

  445. Dilling H, Mombour W, Schmidt MH (2010) Internationale Klassifikation psychischer Störungen. ICD-10. Huber, Bern

    Google Scholar 

  446. EMCDDA (2016) Europäischer Drogenbericht 2016: Trends und Entwicklungen; Europäische Beobachtungsstelle für Drogen und Drogensucht. Luxemburg

    Google Scholar 

  447. Feingold D, Weiser M, Rehm J, Lev-Ran S (2015) The association between cannabis use and mood disorders: A longitudinal study J Affect Disord 172: 211–218

    Google Scholar 

  448. Feingold D, Weiser M, Rehm J, Lev-Ran S (2016) The association between cannabis use and anxiety disorders: Results from a population-based representative sample. Eur Neuropsychopharmacol 26 (3): 493–505. doi: 10.1016/j.euroneuro.2015.12.037

  449. Fergusson DM, Horwood LJ, Swain-Campbell N, (2002) Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97: 1123–1135

    Google Scholar 

  450. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP (2015) Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord 171: 39–47. doi: http://dx.doi.org/10.1016/j.jad.2014.09.016

  451. Henquet C, Krabbendam L, De Graaf R, Ten Have M, Van Os J (2006) Cannabis use and expression of mania in the general population. J Affect Disord 95: 103–110

    Google Scholar 

  452. Jacobi F, Höfler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Maske U, Hapke U, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen H-U (2014) Psychische Störungen in der Allgemeinbevölkerung. Nervenarzt 85: 77–87

    Google Scholar 

  453. Juon HS, Ensminger ME (1997) Childhood, adolescent, and young adult predictors of suicidal behaviors: a prospective study of African Americans. J Child Psychol Psychiat 38: 553–563.

    Google Scholar 

  454. Kedzior KK, Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- A meta-analysis of 31 studies. BMC Psychiat 14. doi: 10.1186/1471-244X-14-136

  455. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J (2014) The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 44 (4): 797–810. doi: http://dx.doi.org/10.1017/S0033291713001438

  456. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895

  457. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (9584): 319–328. doi: http://dx.doi.org/10.1016/S0140-6736%2807%2961162-3

  458. Newcomb MD, Scheier LM, Bentler PM (1993) Effects of adolescent drug use on adult mental health: a prospective study of a community sample. Exp Clin Psychopharmacol 1: 215–241

    Google Scholar 

  459. Newcomb MD, Vargas-Carmona J, Galaif ER (1999) Drug problems and psychological distress among a community sample of adults: predictors, consequences, or confound? . J Commun Psychol 27: 405–429

    Google Scholar 

  460. OCEBM (2011) Levels of Evidence Working Group. The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford

  461. Pacek LR, Martins SS, Crum RM (2013) The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: Results from a national sample. J Affect Disord 148 (2–3): 188–195. doi: http://dx.doi.org/10.1016/j.jad.2012.11.059

  462. Petersen KU, Thomasius R (2007) Auwirkungen von Cannabiskonsum und -missbrauch. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. 1 systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, Lengerich

    Google Scholar 

  463. Renault PF, Schuster CR, Freedman DX, Sikic B, de Mello DN (1974) Repeat administration of marihuana smoke to humans. Arch Gen Psychiat 31: 95–102

    Google Scholar 

  464. Saban A, Flisher AJ, Grimsrud A, Morojele N, London L, Williams DR, Stein DJ (2014) The association between substance use and common mental disorders in young adults: results from the South African Stress and Health (SASH) Survey. Pan Afr Med J 17 Suppl 1: 11–11. doi: 10.11694/pamj.supp.2014.17.1.3328

  465. SIGN (Scottish Intercollegiate Guidelines Network) (2015) Scottish Intercollegiate Guidelines Network 50 Methodology Checklist. Edinburgh, United Kingdom

    Google Scholar 

  466. Tijssen MJ, VanOs J, Wittchen H-U, Lieb R, Beesdo K, Wichers M (2010) Risk factors predicting onset and persistence of subthreshold expression of bipolar psychopathology among youth from the community. Acta Psychiat Scand 122: 255–266

    Google Scholar 

  467. Tyler E, Jones S, Black N, Carter LA, Barrowclough C (2015) The relationship between bipolar disorder and cannabis use in daily life: an experience sampling study.[Erratum appears in PLoS One. 2015;10 (3): e0123953; PMID: 25822166]. PLoS ONE [Electronic Resource] 10 (3): e0118916. doi: http://dx.doi.org/10.1371/journal.pone.0118916

  468. Wilcox HC (2003) The development of suicide ideation and attempt: an epidemiologic study of fi rst graders followed into young adulthood. PhD thesis, John Hopkins University

    Google Scholar 

  469. AIHW (Australian Institute of Health and Welfare) (2014) 2013 National Drug Strategy Household Survey: Detailed Report. Australian Institute of Health and Welfare, Canberra

    Google Scholar 

  470. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) „Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectromet JMS 44 (5): 832–837. doi: 10.1002/jms.1558

  471. Bonnet U, Mahler H (2015) Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard. Fortschr Neurol Psychiatr 83 (4): 221–231. doi: 10.1055/s-0034-1399307

  472. Brewer TL, Collins M (2014) A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Specialist Pediat Nurs JSPN 19 (2): 119–126. doi: 10.1111/jspn.12057

  473. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144: 12–41. doi: 10.1016/j.drugalcdep.2014.08.005

  474. Castellanos D, Gralnik LM (2016) Synthetic cannabinoids 2015: An update for pediatricians in clinical practice. World J Clin Pediat 5 (1): 16

    Google Scholar 

  475. Castellanos D, Singh S, Thornton G, Avila M, Moreno A (2011) Synthetic cannabinoid use: a case series of adolescents. J Adolescent Health 49 (4): 347–349

    Google Scholar 

  476. Coca SG, Singanamala S, Parikh CR (2012) Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81 (5): 442–448

    Google Scholar 

  477. Forrester M, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Human Exp Toxicol 0960327111421945

    Google Scholar 

  478. Giroud C, de Cesare M, Berthet A, Varlet V, Concha-Lozano N, Favrat B (2015) E-Cigarettes: A Review of New Trends in Cannabis Use. Int J Environ Res Public Health 12 (8): 9988–10008. doi: 10.3390/ijerph120809988

  479. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL (2012) „Spice” and „K2” Herbal Highs: A Case Series and Systematic Review of the Clinical Effects and Biopsychosocial Implications of Synthetic Cannabinoid Use in Humans. Am J Addict 21 (4): 320–326. doi: 10.1111/j.1521-0391.2012.00240.x

  480. Hopkins CY, Gilchrist BL (2013) A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 45 (4): 544–546

    Google Scholar 

  481. Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895

  482. Logan B, Reinhold L, Kacinko S (2011) K2 and Beyond: A Synthetic Cannabinoid Primer (K43). In: American Academy of Forensic Sciences, pp 21–26

    Google Scholar 

  483. OCEBM (2011) The Oxford Levels of Evidence 2. Levels of Evicence Working Group. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford

  484. Pabst A, Piontek D, Kraus L, Müller S (2010) Substance use and substance use disorders: results of the 2009 epidemiological survey of substance abuse. Sucht 56: 327–336

    Google Scholar 

  485. Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo-Fabrici E, Bonavigo T (2013) „Spiceophrenia”: A systematic overview of „Spice”-related psychopathological issues and a case report. Human Psychopharmacol Clin Exp 28 (4): 379–389. doi: 10.1002/hup.2312

  486. Papaseit E, Farré M, Schifano F, Torrens M (2014) Emerging drugs in Europe. Curr Opin Psychiat 27 (4): 243–250. doi: 10.1097/YCO.0000000000000071

  487. Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch: eine Expertise zu gesundheitlichen und psychosozialen Folgen; ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publ., Lengerich

    Google Scholar 

  488. Plumb J, McDonnell WM, Anderson KT, Crouch BI, Caravati EM Adverse effects from pediatric exposures to spice (cannabinoid agonists). In: Clinical Toxicology, 2012. vol 7. Informa Healthcare 52 Vanderbilt Ave, New York, NY 10017 USA, pp 708–708

    Google Scholar 

  489. SIGN (2015) Scottish Intercollegiate Guidelines Network 50 Methodology Checklist. Edinburgh, United Kingdom

    Google Scholar 

  490. Smith K, Flatley J (2011) Drug misuse declared: findings from the 2010/11 British crime survey. England and Wales Home Office 27

    Google Scholar 

  491. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Philadelphia) 54 (1): 1–13. doi: 10.3109/15563650.2015.1110590

  492. Teske J, Weller J-P, Fieguth A, Rothämel T, Schulz Y, Tröger HD (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl- (1-pentylindol-3-yl) methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B 878 (27): 2659–2663

    Google Scholar 

  493. Ukaigwe A, Karmacharya P, Donato A (2014) A gut gone to pot: A case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med 2014

    Google Scholar 

  494. van Amsterdam J, Brunt T, van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29 (3): 254–263. doi: 10.1177/0269881114565142

  495. Winstock A, Lynskey M, Borschmann R, Waldron J (2015) Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol 29 (6): 698–703. doi: 10.1177/0269881115574493

  496. Winstock AR, Barratt MJ (2013) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Human Psychopharmacol Clin Exp 28 (4): 390–393

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Schneider, M. et al. (2019). Cannabiskonsum zum Freizeitgebrauch. In: Hoch, E., Friemel, C.M., Schneider, M. (eds) Cannabis: Potenzial und Risiko. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57291-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57291-7_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57290-0

  • Online ISBN: 978-3-662-57291-7

  • eBook Packages: Medicine (German Language)